Biocon rises nearly 6% after Q2 profit falls 52%
In short
Biocon shares climbed nearly 6% even after the company said Q2 consolidated net profit fell 52% to ₹41 crore. Revenue from operations increased 2%, and the stock had recently touched a 52-week low of ₹318.40 on the NSE.
The mixed numbers matter because investors were watching both weaker profit and a small rise in revenue while the stock moved off its recent low.
What the reporting says
Biocon shares rose nearly 6% after the company reported a 52% drop in Q2 consolidated net profit to ₹41 crore, while revenue from operations grew 2%. The stock had recently hit a 52-week low of ₹318.40 on the NSE.
Why it matters
Biocon reported a steep fall in quarterly profit to ₹41 crore, but revenue still grew 2%, and the stock later rose nearly 6% despite having recently hit a 52-week low on the NSE. The move is relevant to Biocon shareholders and broader pharma-market sentiment.